Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-01: AZD5335 vs mirvetuximab soravtansine or chemotherapy in platinum-resistant ovarian cancer (Japan)
jRCT2051250229Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Randomised trial of AZD5335 in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival (FRα-high cohort AZD5335 vs mirvetuximab soravtansine) and Progression-free survival (FRα-low cohort AZD5335 vs investigator-choice chemotherapy). Started Apr 2026; status: recruiting.
02
Drugs
AZD5335
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2051250229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250229.